Company intelligence / Profile preview

Repairon GmbH

Göttingen, Lower Saxony (Niedersachsen), Germanyrepairon.de ↗

Ownership: Private
Employees: ~50
Development stage: Phase 1

Overview

The company has achieved first-in-patient evidence of effective heart repair using its iPSC-derived engineered heart muscle patches in advanced heart failure as part of the BioVAT-HF Phase 1/2 trial. Strong preclinical data support safety, feasibility, and function. GMP manufacturing authorization has been obtained. No active trials are currently listed on ClinicalTrials.gov as of the latest available data.

Therapeutic areas: Cardiovascular
Modalities: Induced pluripotent stem cell (iPSC)-based engineered tissuesEngineered Human Myocardium (EHM) patches
Industry: Biotech

Drug pipeline

1 asset

BioVAT

Unknown

Beyond the preview

Go deeper on Repairon GmbH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Repairon GmbH.

Explore the full profile